QT Imaging Holdings (QTI) Q3 2024 earnings summary

Executive summary

• Entered into a $2.56 million PIPE financing on November 12, 2024, issuing 4,383,558 shares at $0.584/share and warrants at $0.672/share to related parties, including conversion of a $1.56 million note.

• PIPE investors include directors and affiliates, with customary registration rights and lock-up provisions.

• Achieved $1.0 million in commercial revenue for Q3 2024, primarily from scanner sales, with a 63% gross margin.

• Completed engineering and clinical feasibility study with a strategic partner and shipped two scanners to clinical sites.

• Renewed a five-year NIH/NCI research grant for the third year, supporting ongoing R&D collaborations.

Significant events and developments

• PIPE financing provides critical liquidity, with shares and warrants issued to insiders and affiliates.

• Extension Note of $1.56 million surrendered for equity and warrants as part of the PIPE.

• Amended $10 million convertible note, reducing principal and extending maturity to March 2026, with lower monthly payments starting February 2025.

• PIPE financing at a 10% premium to recent share price, with closing expected by November 29, 2024.

• Leadership update: Bilal Malik, PhD, rejoined as Chief Science Officer.

Financial highlights

• Q3 2024 revenue was $1.0 million, down from $1.7 million in Q2 2024 but up from less than $0.1 million in Q3 2023.

• Gross margin improved to 63% in Q3 2024 from 51% in Q2 2024.

• Net loss for Q3 2024 was $3.6 million, including $1.5 million in convertible note interest.

• Adjusted EBITDA for Q3 2024 was $(2.2) million.

• Net cash used in operating activities was $1.9 million in Q3 2024.